Healthcare has long relied on global innovation. Scientific breakthroughs cross borders, investment flows through international networks, and new therapies improve patient outcomes worldwide. Yet growth is increasingly shaped by local realities. As governments exert greater influence over pricing, access, and policy, healthcare leaders face a new challenge: preserving the benefits of global scale while building the regional agility needed to compete.
Few industries are as inherently global as healthcare. Scientific breakthroughs cross borders, clinical evidence travels worldwide, and a therapy that treats cancer, diabetes, or heart disease delivers the same clinical value regardless of geography.
Increasingly, however, commercial success is determined much closer to home.
The challenge today lies not in the science, but in the commercial systems that connect innovation to patients. For decades, governments have taken an ever-increasing role in shaping access and affordability. Pricing decisions in one country increasingly influence expectations elsewhere, while regulatory pathways continue to diverge. Geopolitical tensions are also reshaping trade relationships and supply chains.
For healthcare leaders, this creates a fundamental shift. Success no longer depends solely on developing globally competitive products, but on navigating increasingly fragmented political, regulatory, and commercial environments.
The economics of innovation are shifting
Perhaps nowhere is this shift more visible than in pharmaceutical pricing. Today, approximately 67% of innovative pharmaceutical revenues are generated in the United States. The EU4 plus UK markets account for roughly 16%, while Japan contributes about 4 to 5%. The US accounts for a disproportionate share of global pharmaceutical revenues, reflecting on average 3-4 times higher prices in the US compared to ex-US markets and a greater willingness to fund innovation than many other developed markets and a greater willingness to fund innovation than many other developed markets.
Policies such as Most Favored Nation pricing and international reference pricing have intensified the debate around global pricing disparities. Whether specific policies evolve or change over time is less important than the broader trend. Governments are placing greater scrutiny on healthcare spending and questioning long-standing pricing structures. US policymakers argue that American patients and payers carry a disproportionate share of the global innovation burden.
For pharma companies, the strategic consequences are immediate:
- Lower US prices without higher ex-US prices would compress global revenue pools
- Persistently low willingness to pay outside the US could affect launch sequencing
- Access to innovative medicines could diverge more sharply between markets
Companies increasingly face a difficult calculation. Delayed or restricted launches outside the US can become economically rational if pricing gaps remain too wide. That outcome would be difficult for patients, health systems, and the industry itself. It would also signal a deeper change in how global healthcare innovation and progress are funded in the future.
This makes governmental affairs and policy shaping the core growth capability of every pharmaceutical and biotech company. Market access, pricing, evidence generation, and government engagement can no longer be treated as downstream commercial activities. Increasingly, they determine whether global innovation translates into regional growth.
Supply resilience as part of the growth agenda
A different form of regional risk is visible in generics. Many health systems still depend heavily on China and India for essential generic medicines, including antibiotics. That concentration did not happen by accident. Years of pricing pressure via tender-like procurement of generic medicines in most developed markets around the globe pushed manufacturers toward the lowest-cost production locations and favored ultra-low-cost providers, creating supply chains optimized for efficiency and scale.
Essential medicines can become vulnerable when production is concentrated in only a small number of geographies. Antibiotics sit at the center of modern healthcare, supporting everything from routine surgery to cancer treatment and critical care. A serious disruption in supply would not remain a procurement problem for long. It would quickly become a health system crisis.
COVID-19 exposed the risks of concentrated supply chains, yet many of those vulnerabilities remain. Regional production capacity has expanded only slowly, particularly in categories where low prices leave little room for investment. Additional regulatory and environmental costs further weaken the economics of onshoring to Europe and North America. Without meaningful policy support and higher achievable prices for generic medicines, manufacturers will continue to favor the lowest-cost production footprint.
For healthcare organizations, this creates a new source of competitive advantage. Regional resilience can strengthen relationships with governments, reduce exposure to disruption, and protect continuity of care. It can also support a more credible growth story in markets where healthcare security has become a political priority.
Areas where resilience matters most include:
- Critical generics with limited alternative sources
- Antibiotics and other medicines essential to everyday clinical care
- Manufacturing footprints exposed to trade conflict or geopolitical disruption
Reliable supply is becoming a strategic differentiator in its own right. Companies that invest in control, redundancy, and regional capability will be better positioned to navigate disruption and sustain growth through periods of uncertainty.
Why healthcare companies need to rebalance global and regional decision-making
Healthcare has always been a local business in one important respect: decisions around reimbursement, regulation, and funding are made close to national health systems. What has changed is the speed at which those decisions shape commercial outcomes. Centralized organizations still play a vital role in setting direction and maintaining consistency across the business. Difficulties emerge when decisions that depend on local market realities must move through layers of approval far removed from the market, or when decisions with cross-market implications are made without sufficient global coordination.
The next source of sustainable growth will come from putting decisions at the right level of the organization. Regional and country teams need clearer decision rights where market conditions demand local responsiveness, within a global framework that maintains alignment on issues with implications across markets. This balance will differ by sector and by decision. In pharma, for example, the growing importance of international reference pricing and policies such as MFN can increase the interdependence of pricing decisions across countries, strengthening the need for global coordination. In MedTech and diagnostics, by contrast, procurement pathways, regulation, tariffs, and customer dynamics can create a stronger case for regional or local autonomy.
For leadership teams, the challenge is determining which decisions benefit from local flexibility and which require global ownership. Product launches, go-to-market models, and responses to changing customer or procurement dynamics may need to reflect regional realities. Pricing decisions, meanwhile, can require tighter global coordination where actions in one market increasingly affect outcomes in others. The goal is not decentralization for its own sake, but an operating model that allows decisions to be made at the level best equipped to respond.
This shift is particularly important in MedTech and diagnostics, where changes in tariffs, procurement policy, or regulation can rapidly reshape competitive positions. A company with European manufacturing, for example, can face sudden disadvantages in the US if tariffs change the economics overnight. Clear regional decision rights give organizations a better chance of responding before margin pressure becomes market share loss.
The next era of healthcare growth
Scientific progress remains the foundation of healthcare growth. Innovation, clinical evidence, and sustained investment in R&D continue to drive the industry forward. But commercial success now depends on a wider set of capabilities. Leaders must understand how pricing power shifts across markets while engaging more actively in policy debates. They also need to strengthen resilience across supply networks and depending on the healthcare sub-industry give regional teams the autonomy to act within a given pricing band with greater speed and confidence.
The mandate for healthcare organizations is clear and increasingly urgent:
- Rebalance revenue exposure beyond excessive dependence on one market
- Build regional resilience before disruption forces action
The industry is entering a period of fundamental realignment. Assumptions that supported growth for decades are coming under pressure, particularly where organizations remain heavily dependent on a single revenue engine, concentrated supply networks, or highly centralized decision-making.
The winners will be those that recognize the transformational shift taking place across healthcare. Scientific innovation may remain global. But commercial success will increasingly be determined closer to the patient, the payer, and the policymaker. Healthcare's next generation of market leaders will be those that preserve the advantages of global science while building the regional agility to compete.